{"id":11184,"date":"2024-05-31T10:25:14","date_gmt":"2024-05-31T02:25:14","guid":{"rendered":"https:\/\/vaxlab.dukekunshan.edu.cn\/?post_type=publications&#038;p=11184"},"modified":"2024-05-31T10:25:19","modified_gmt":"2024-05-31T02:25:19","slug":"cost-effectiveness-analysis-of-vaccination-strategies-against-meningococcal-disease-for-children-under-nine-years-of-age-in-china","status":"publish","type":"publications","link":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/publications\/cost-effectiveness-analysis-of-vaccination-strategies-against-meningococcal-disease-for-children-under-nine-years-of-age-in-china\/","title":{"rendered":"Cost-effectiveness analysis of vaccination strategies against meningococcal disease for children under nine years of age in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">This study was conducted by Hai Fang and his team from Peking University and published in <em>Human Vaccines &amp; Immunotherapeutics<\/em>. The study evaluated the cost-effectiveness of using non-immunization program vaccines as an alternative to current vaccination strategies and simulated the economic and health consequences of meningococcal disease using four vaccination strategies based on the 2019 birth cohort. The result showed that using quadrivalent polysaccharide vaccine (MPV-4), bivalent conjugate vaccine (MCV-AC), and quadrivalent conjugate vaccine (MCV-4) could have increased health benefits but at a higher cost. The new strategies would be cost-effective provided lowering vaccine price.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This study was conducted by Hai Fang and his team from Peking University and published in Human Vaccines &#038; Immunotherapeutics. The study evaluated the cost-effectiveness of using non-immunization program vaccines as an alternative to current vaccination strategies and simulated the economic and health consequences of meningococcal disease using four vaccination strategies based on the 2019 birth cohort. The result showed that using quadrivalent polysaccharide vaccine (MPV-4), bivalent conjugate vaccine (MCV-AC), and quadrivalent conjugate vaccine (MCV-4) could have increased health benefits but at a higher cost. The new strategies would be cost-effective provided lowering vaccine price.<\/p>\n","protected":false},"featured_media":11144,"parent":0,"template":"","meta":{"type_label":"none_selected"},"class_list":["post-11184","publications","type-publications","status-publish","has-post-thumbnail","hentry"],"_links":{"self":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/publications\/11184","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/publications"}],"about":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/types\/publications"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/media\/11144"}],"wp:attachment":[{"href":"https:\/\/vaxlab.dukekunshan.edu.cn\/en\/wp-json\/wp\/v2\/media?parent=11184"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}